Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences

Apr 12, 2024

Featuring perspectives from Dr Bita Fakhri, including the following topics:

• Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
• 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
• Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
• 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
• Current clinical role of MRD testing for CLL (28:11)
• Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
• 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
• Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
• Recent updates for the management of double-refractory CLL (58:05)
• Novel therapies under investigation for patients with CLL/SLL (1:10:57)
• Key findings guiding the clinical management of Richter’s transformation (1:13:44)
• Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)

CME information and select publications